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Abstract 30 
Background: Normotensive pregnancy may develop into preeclampsia (PE) and other adverse 31 
pregnancy complications (APCs), for which the causes are still unknown.  Suboptimal Health 32 
Status (SHS), a physical state between health and disease, might contribute to the development 33 
and progression of PE. By integration of a routine health measure in this Ghanaian Suboptimal 34 
Health Cohort Study, we explored the usefulness of a 25-question item SHS questionnaire 35 
(SHSQ-25) for early screening and prediction of normotensive pregnant women (NTN-PW) 36 
likely to develop PE.  37 
Methods: We assessed the overall health status among a cohort of 593 NTN-PW at baseline 38 
(10-20 weeks gestation) and followed them at 21-31 weeks until 32-42 weeks. After an average 39 
of 20 weeks follow-up, 498 participants returned and were included in the final analysis. 40 
Haematobiochemical, clinical, and socio-demographic data were obtained.  41 
Results:  Of the 498 participants, 49.8% (248/498) had ‘high SHS’ at baseline [61.7% 42 
(153/248) later developed PE] and 38.3% (95/248) were NTN-PW whereas 50.2% (250/498) 43 
had ‘optimal health’ [17.6% (44/250) later developed PE] and 82.4% (206/250) were NTN-44 
PW. At baseline, high SHS score yielded a significantly (p<0.05) increased adjusted odds ratio, 45 
a wider area under the curve (AUC), and a higher sensitivity and specificity for the prediction 46 
of PE (3.67; 0.898; 91.9% and 87.8%), PE coexisting with intrauterine growth restriction (2.86, 47 
0.838; 91.5% and 75.9%),  stillbirth (2.52; 0.783; 96.6% and 60.0%),  haemolysis elevated 48 
liver enzymes and low platelet count (HELLP) syndrome (2.08; 0.800; 97.2% and 63.8%), 49 
acute kidney injury (2.20; 0.825; 95.3% and 70.0%) and dyslipidaemia (2.80; 0.8205; 95.7% 50 
and 68.4%) at 32-42 weeks gestation.  51 
Conclusions: High SHS score is associated with increased incidence of PE; hence, SHS can 52 
be used independently as a risk stratification tool for adverse pregnancy outcomes thereby 53 
creating an opportunity for predictive, preventive and personalised medicine.  54 
 55 
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 59 
Introduction  60 
Given the advances in research and technology, one would expect that pregnancy and 61 
childbirth should be safe without mortalities. To date, however, this expectation has 62 
largely been a mirage [1]. An estimation from the United Nations Maternal 63 
Mortality Estimation Inter-Agency Group and the current World Health Organisat ion 64 
(WHO), shows that the regional maternal mortality rate was estimated at 546 deaths per 65 
100,000 live births in sub-Saharan Africa (SSA) [1]. One of the main causes of these 66 
disturbing estimates is preeclampsia (PE).  67 
Preeclampsia (PE) (ICD-10-014) is a disorder of pregnancy characterised by a 68 
combination of measurable proteinuria and hypertension after 20 weeks of gestation, in 69 
pregnant women who were previously normotensive [2]. PE is associated with mult i-70 
organ dysfunction and other adverse pregnancy complicat ions (APCs) such as stillbirt h, 71 
intrauterine growth restriction (IUGR), fetal d istress and death, abruptio placenta and 72 
HELLP syndrome [3, 4]. PE afflicts about 5 to 8 percent of all pregnancies worldwide [1] 73 
and is responsible for up to 4% of all maternal morbidities and mortalities in sub-Saharan 74 
Africa (SSA) [5, 6].  75 
Despite its positive association with maternal morbidities and mortalities, the 76 
aetiology of PE is not fully understood. The unclear pathogenesis of PE is now a dilemma 77 
for clinicians and researchers working to develop appropriate therapeutic and diagnost ic 78 
measures, aside from delivery of the placenta and the baby under intensive care which 79 
remain the major protective measures for PE [2]. The stressful demands of pregnancy 80 
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may cause pregnant mothers to present with poor health complaints and this has led to an 81 
unexpected onset of PE and delayed therapeutic intervention among normotensive 82 
pregnant women (NTN-PW) who were previously devoid of a diagnosable condition [7]. 83 
Since an early detection coupled with appropriate therapeutic intervention is important in 84 
preventing the clinical manifestation of diseases, there is the need for clinicians to shift  85 
from the perspective of delayed intervention approach to predictive, preventive and 86 
personalised medicine (PPPM) [8-10]. A paradigm shift from reactive to PPPM would  87 
allow screening of patients at the preclinical or suboptimal stage before the onset of a 88 
disease [11]. PPPM has over the past few years adopted environmental, traditional and 89 
behavioural factors to solving public health conditions, and this approach has impacted  90 
significantly on the prevention and treatment of chronic diseases [11]. The perspective of 91 
PPPM if integrated into maternal and neonatal health screening may inform early 92 
detection of PE onset and improve diagnosis, prevention, and therapeutics. There is an 93 
urgent need to screen and identify normotensive pregnant women who may be 94 
experiencing poor health prior to the onset of PE.  95 
In recent public health studies, a search for an inexpensive, less turnaround time 96 
and a non-invasive health screening measure has yielded a 25-question item of suboptimal 97 
health status questionnaire (SHSQ-25) [12]. SHSQ-25 represents a new PPPM, which can 98 
be used in both health care and field/community settings to identify individuals who 99 
complain of poor health without a diagnosable condition [12, 13]. Over the past few years, 100 
SHSQ-25 has made a significant impact on the field PPPM and has been used to explain 101 
the concept of suboptimal health status (SHS), which is defined as the overall physical 102 
state between health and disease [12, 14, 13]. The SHSQ-25 expresses the overall health 103 
of an individual from five domains- including fatigue, cardiovascular, digestive, immune 104 
and mental health [12, 13]. SHS represents a subclinical reversible stage of chronic 105 
disease and is typified by health complaints, low energy, and general weakness within 106 
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three months [14, 15]. The SHSQ-25 has been previously used in our previous studies as 107 
a potential risk stratification measure for cardiovascular and other chronic diseases in 108 
different populations including Asia [16-18] and Africa [19]. Also, SHSQ-25 was used  109 
along with the endothelial dysfunction (ED) index to predict the onset of cardiovascu la r 110 
disease in an European population [20]. Furthermore, SHS was found to be associated  111 
with telomere length [21], psychosocial stress, plasma cortisol and mRNA expression of 112 
glucocorticoid receptor a/b in lymphocytes in a Chinese population [22].  113 
Although SHS has been associated with blood pressure disorders, no study to date 114 
has explored the usefulness of SHSQ-25 in pregnancy and childbirth. While previous 115 
studies extensively explored SHS from the perspective of PPPM in several chronic 116 
conditions, its relevance as a predictive measure PE onset has not been reported. Thus, 117 
we examined the potential of the subjective tool, SHSQ-25 along with clinical biochemical 118 
measures for prediction and early identification of suboptimal health in normotensive pregnant 119 
women likely to develop PE coexisting with and without other adverse pregnancy 120 
complications (APCs). The findings of this study is expected to increase our knowledge of 121 
the pathogenesis of PE and create a window of opportunity for predictive, preventive and 122 
personalised medicine (PPPM) specific measures such as risk assessment, screening 123 
programmes and targeted prevention [8-10].  124 
 125 
Methods  126 
Study design/study participants  127 
This prospective cohort study included 593 normotensive pregnant women (NTN-PW) 128 
aged from 18 to 45 years who had no history of a clinically diagnosed disease in the last three 129 
months and were visiting the antenatal clinic at the Komfo Anokye Teaching Hospital 130 
(KATH), Kumasi, Ghana from June 2017 to December 2018. Pregnant women were 131 
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initially contacted through a letter of introduction and were invited via a phone call for 132 
an interview as well as clinical and biochemical evaluation. Both nulliparous and 133 
multiparous pregnant women with a singleton pregnancy were contacted. After written 134 
informed consent and ethical consideration, all participants were physically examined and 135 
assessed by a qualified consultant obstetrician/gynaecologist before inclusion in the 136 
study. Exclusion criteria were women with a twin pregnancy, those below 18 years, 137 
advanced maternal age (>45years), previous history of preeclampsia, gestational diabetes, 138 
gestational hypertension, obesity, hyperlipidaemia, cancers, smoking, alcoholism, 139 
sexually transmitted infections, sickle cell anaemia, cerebrovascular conditions and 140 
cardiovascular conditions of any form. 141 
 Baseline assessment of SHS  142 
At baseline [10-20 weeks gestation (average gestation of 17 weeks)] the overall health 143 
status of 593 NTN-PW was measured using a validated SHSQ-25. The SHSQ-25 is made 144 
up of five domains namely; fatigue, cardiovascular system, digestive system, immune 145 
system and mental health (Fig. 1). These questions were explained to each participant in 146 
the native Ghanaian language and their responses were translated into English by the 147 
consultant obstetrician/gynaecologist with 100% accuracy. Based on how often each 148 
pregnant woman had experienced a particular health complaint in the last three months, 149 
they were asked to rate a health statement on a 5-point Likert scale: never or almost never 150 
(1), occasionally (2), often (3), very often (4) and always (5). These scores were recoded  151 
as 0-4 followed by a summation of the codes for the 25 answered items. The median of 152 
the total score was recorded as the cut-off point and values ≥ the cut-off represented ‘high 153 
SHS’ (Poor health) and those ˂ the cut-off indicates ‘optimal health’ [14, 15, 13]. In this 154 
study, a median score ≥ 19 depicted high SHS and <19 depicted optimal health status 155 
(OHS). A Cronbach’s alpha coefficient value of 0.95 was found after testing the reliabi l ity 156 
of SHSQ-25. SHS was measured for all participants at baseline (10-20 weeks) only.  157 
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Sociodemographic, obstetric and clinical assessment 158 
Information regarding socio-demographic characteristics such as age, highest level of 159 
education attained, occupational history, household income as well as obstetric data such as 160 
parity, gravidity, gestational age, contraceptive use, family history of hypertension and 161 
previous pregnancy complications were obtained via the antenatal folder and the participant’s 162 
record in the hospital database. Blood pressure (BP) in mmHg was measured by t rained  163 
personnel and midwives using mercury sphygmomanometers (Accoson, England) and a 164 
stethoscope following recommendations by the National High Blood Pressure Education 165 
Program (NHBEP) working group (2000). The procedure was performed twice at a 5 to 166 
10-minute interval for each participant after the first measurement. The average values of 167 
the two measurements were recorded as the BP. Participants were classified as 168 
normotensive pregnant women if their pregnancy was without measurable proteinuria and 169 
blood pressure was ≤ 120/80 mmHg on two (2) occasions at least four (4) hours apart . 170 
Weight and height were read and recorded to the nearest 0.1 kilogram and 0.1 centimetres, 171 
respectively. Briefly, pregnant women were made to stand on a weighing scale (Seca 762 172 
Mechanical Personal Scale, Hamburg, Germany) and against the stadiometer (Seca 213 173 
Portable Height Measuring Rod Stadiometer, Hamburg, Germany) without their shoes, 174 
belongings or any extraneous weight. The body mass index (BMI) was calculated with 175 
the formula (weight/height2) and written in kg/m² units. Pre-gestation BMI was recorded . 176 
Proteinuria was measured using a urine reagent dipstick (a semi-quantitat ive colour scale 177 
on the URIT 2VPG Medical electronic Co., Ltd. China). The absence of proteinuria was 178 
recorded as ‘negative’. The presence of protein in urine was recorded as ≥ 0.3g/l on 179 
microalbuminuria or ≥ 1+ on dipstick urinalysis. For each pregnant woman, the BP, BMI , 180 
and proteinuria were measured at three (3) time points (10-20 weeks, 21-31 weeks and 181 
32-41 weeks) and data recorded.   182 
 183 
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Follow-up and the events of preeclampsia  184 
After an average period of 20 weeks follow-up from baseline until birth, 498 out of 593 185 
participants returned for delivery and were included in the final assessment. By the time 186 
of delivery, 301 had normal blood pressure without proteinuria (i.e. NTN-PW) and were 187 
classified as control, whereas 197 developed PE and were classified as cases. Of the 498 188 
participants, 248 of them had ‘high SHS’ at baseline (153 later developed PE and 95 were 189 
NTN-PW) whereas 250 had ‘optimal health’ at baseline (44 developed PE and 206 were NTN-190 
PW). Of the initial 593 participants, 95 women comprising 89 and 6 participants were lost  191 
to follow-up and thus did not partake in the first (21-31 weeks gestation) and second (32-192 
42 weeks gestation) follow-ups, respectively (Fig. 2). The reasons for these losses were 193 
unwillingness to continue (n=32), relocation (n=48), spontaneous abortion (n=4) and self -194 
induced abortion (n=11).  195 
Participants were physically examined and diagnosed in addition to the examination of 196 
selection criteria by a qualified consultant Obstetrician/Gynaecologist . Preeclampsia 197 
(ICD-10-CM-014) was defined as the presence of proteinuria (≥ 1+ or 0.3g/l) and 198 
hypertension (≥ 140/90 mmHg) on two (2) occasions at least four (4) hours apart detected 199 
after the 20th week of gestation in pregnant women who were previously normotensive. 200 
Alternatively, high blood pressure combined with multisystemic manifestations such as 201 
HELLP syndrome, renal insufficiency, pulmonary oedema, and visual or cerebral 202 
disturbances supported the diagnosis of PE even in the absence of proteinuria [23]. 203 
Biochemical evaluation 204 
Fasting venous blood samples were collected in the morning hours (8 am to 11 am) from 205 
each pregnant woman into vacutainer® tubes. Plasma and serum were separated into two 206 
cryovials and stored at -80oC (Thermo Scientific™ Freezers, USA) until analysis.  207 
Biochemical measures including fasting blood glucose (FBG), triglyceride (TG), and total 208 
cholesterol (TC), high density lipoprotein cholesterol (HDL-c), low density lipoprote in 209 
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cholesterol (LDL-c), alanine aminotransferase (ALT), aspartate aminotransferase (AST), 210 
gamma-glutamyl transferase (GGT), total protein (TP), albumin (ALB), lactate 211 
dehydrogenase (LDH), alkaline phosphatase (ALP), urea, creatinine (Cr), uric acid (UA), 212 
sodium (Na), potassium (K), chloride (Cl-), magnesium (Mg), and calcium (Ca) were 213 
measured using an automatic chemistry analyser (Roche Diagnostics, COBAS INTEGRA 214 
400 Plus, USA). Haemoglobin and red blood cell distribution width (RDW) were analysed  215 
using the Mindray Haematology Analyzer BC 2800. These haematobiochemica l 216 
determinations were performed at three-time points (10-20 weeks, 21-31 weeks and 32-217 
41 weeks) for each participant.   218 
Diagnostic criteria for adverse pregnancy complications  219 
IUGR, stillbirth, HELLP syndrome and acute kidney injury (AKI) were diagnosed by a 220 
qualified consultant obstetrician/gynaecologist following the criteria of ICD-10-036.5990 221 
[24], ICD-10-Z37.1 [24], ICD-10-014.2 [25] and ICD-10-N17 [26], respective ly. 222 
Dyslipidaemia was classified based on the National Cholesterol Education Programme Adult 223 
Treatment Panel III (NCEP-ATP III) criteria as reduced HDL-c <1.29 mmol/L or specific 224 
treatment for this lipid abnormality, raised TG ≥1.7 mmol/L or specific treatment for this lipid 225 
abnormality, TC >6.2 mmol/l, and LDL-c >3.37 mmol/l [27].  226 
Statistical analysis 227 
Data were analysed using SPSS version 24 (IBM Corp, NY, USA), XLSTAT Premium 228 
version 2018.1 and R version 3.4.3 (R core Team 2017). The normality of the data was 229 
performed using the Kolmogorov-Smirnov test. Data was presented as mean ± SD for 230 
parametric continuous variables, median (interquartile ranges) for non-paramet r ic 231 
continuous variables and frequency (percentages) for categorical variables. A Chi-square 232 
test was used to test the association between the proportion of high SHS and optimal 233 
health status normotensive pregnant women. Mean comparison between three 234 
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independent variables was performed using one-way ANOVA followed by Bonferroni 235 
post-hoc multiple comparison test. Median comparison between three independent  236 
variables was performed using Kruskal Wallis one-way ANOVA followed by Bonferroni 237 
post-hoc multiple comparison test. Since neither the SHS nor PE incidence data meets the 238 
assumptions for Pearson’s correlation, Spearman Rho correlation was used to test  239 
association between the individual SHS-specific domains scores and the incidence of PE. 240 
Benjamini Hochberg correction was performed to adjust for false discovery rates. A 241 
multivariate logistic regression model was performed to test the association between SHS 242 
and PE with and without adverse pregnancy complications and adjusted odds ratios (aOR) 243 
were recorded. A receiver operating characterist ic (ROC) curve and area under the curve 244 
(AUC) were generated to evaluate the diagnostic performance of the model. P< 0.05 was 245 
considered statistically significant .  246 
 247 
Results 248 
 249 
A total of 593 normotensive pregnant women (NTN-PW) were assessed at baseline. Of 250 
these, 498 of them returned and were included in the final analysis. At baseline, a higher 251 
proportion of NTN-PW had completed secondary education (41.8%), were married  252 
(83.5%), were Akan (81.7%) by ethnicity, had an informal occupation (66.1%), had low 253 
basic monthly income (38.4%), were nulliparous (36.9%), were primigravida (46.8%), 254 
and had no history of family hypertension (77.9%), spontaneous abortion (72.1%) and 255 
caesarean section (80.1%). When the 498 NTN-PW were stratified into high SHS and 256 
optimal health status (OHS) from baseline, NTN-PW with high SHS had a significant ly 257 
increased percentage history of spontaneous abortion (36.7% vs. 19.2%; p =0.0001), 258 
nulliparity (41.1% vs. 32.8%; p =0.0202) and primigravidity (62.9% vs. 30.8%; p 259 
<0.0001) compared to those with optimal health. None of the NTN-PW had proteinur ia 260 
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at baseline. There was a statistically significant difference between the mean level of SBP 261 
among NTN-PW with high SHS compared to those with optimal health (116.0 vs. 113.2; 262 
p =0.0036). Meanwhile, there was no statistically significant difference between the mean 263 
age, gestational age, DBP, pre-gestational and gestational BMI among high SHS NTN -264 
PW compared to those with optimal health (p >0.05) (Table 1).  265 
A total of the 498 participants completed the study. Of the 498 participants, 248 of them 266 
representing 49.8% (248/498) had ‘high SHS’ at baseline (10-20 weeks gestation). Of the 267 
248 high SHS participants, 61.7% (153/248) later developed PE whereas 38.3% (95/248) 268 
were NTN-PW. Conversely, 250 of the 498 participants representing 50.2% (250/498) had 269 
‘optimal health’ at baseline. Of the 250 optimal health participants, 17.6% (44/250) later 270 
developed PE whereas 82.4% (206/250) were NTN-PW. When the high SHS and optimal 271 
health participants were stratified into pregnant women who later developed PE (PWLD -272 
PE) and NTN-PW at baseline, high SHS PWLD-PE had significantly increased SBP 273 
(118.3 vs. 112.4; p <0.0001), DBP (75.05 vs. 69.91; p =0.0002), ALT (14.3 vs 10.7; p 274 
<0.0001), ALP (97 vs 70; p =0.0002), urea (4.34 vs. 3.55; p =0.0011), creatinine (65.61 275 
vs. 56.92; p <0.0001), uric acid (326.0  vs 286.0; p =0.0034) and triglyceride (1.56 vs. 276 
1.21; p =0.0003) but significantly lower levels of serum Mg (0.88 vs. 0.96; p =0.0082) 277 
and albumin-ad justed calcium (2.03 vs. 2.20; p =0.0004) compared to high SHS NTN-278 
PW. Optimal health PWLD-PE had significantly higher ALP (95 vs. 91.5; p =0.0006), 279 
UA (304.9 vs. 275.3; p =0.0039) and TG (1.44 vs 1.16; p =0.0031) compared to optimal 280 
health NTN-PW (Table 2). 281 
As depicted in Table 3, when the high SHS were stratified into PE and NTN-PW at 32-282 
42 weeks gestation, there were significantly (p <0.0001) elevated levels of SBP, DBP, 283 
Na, LDH, AST, ALT, ALP, GGT, urea, creatinine, UA, and TG among PE women 284 
compared to NTN-PW, who previously had high SHS at baseline. Conversely, PE women 285 
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were at an increased risk of preterm delivery as depicted by a significantly lower 286 
gestational age than NTN-PW who previously had high SHS at baseline. Additionally, 287 
levels of Mg, Ca, total protein, albumin, and platelet (PLT) count were significant ly 288 
reduced among PE women compared to NTN-PW, who previously had high SHS at 289 
baseline sampling.  290 
At 32-42 weeks gestation when participants who previously had optimal health were 291 
stratified into PE and NTN-PW, there were a significantly (p <0.0001) elevated levels of 292 
SBP, DBP, LDH, AST, ALT, ALP, GGT, urea, creatinine, UA, and TG but a reduced GA, 293 
Mg, Ca, total protein, albumin, platelet (PLT) count  and baby birthweight in PE 294 
compared to the NTN-PW.  295 
Furthermore, when PE women who previously had high SHS were compared to PE 296 
women who previously had optimal health, there were a statistically significantly (p 297 
<0.05) lower GA, Mg, Ca, total protein, and albumin levels, but elevated levels of SBP, 298 
LDH, AST, ALT, ALP. Also, when NTN-PW who previously had high SHS were 299 
compared to NTN-PW who previously had optimal health at 32-42 weeks gestation, there 300 
were statistically significantly (p <0.05) lower levels of serum Mg and Ca, but elevated  301 
levels of SBP (Table 3).  302 
On exploring the association between the incidence of PE and the individual SHS domain 303 
score (Table 4), there was a significant positive correlation between PE incidence and 304 
Fatigue (r=0.300; p =0.0038), Cardiovascular system (r=0.291; p =0.0174), digestive 305 
system (r=0.287; p =0.0291), immune system (r=0.342; p =0.0010), mental health status 306 
(r=0.442; p <0.0001) and the overall SHS score (r=0.509; p <0.0001) (Table 4).  307 
The univariate logistic regression analysis explained that, high BP, low Mg, low Ca, low 308 
Hb, low HDL, high LDH, high AST levels, high creatinine and high TG levels yielded a 309 
significantly increased odds ratio for predicting high SHS among NTN-PW at baseline 310 
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who later developed PE. After adjusting for confounding factors on multivariate analysis, 311 
the association remained significant and the odds ratios were only slightly attenuated if  312 
at all. Overall, high BP [aOR=2.84, 95% CI (1.94-5.40), p =0.0314], low Mg [aOR= 2.99, 313 
95% CI (1.29-6.20), p =0.0038] and low Ca [aOR=4.20, 95% CI (1.57-5.63), p <0.0001], 314 
high TG [aOR= 2.08, 95% CI (1.12-4.27), p =0.0151] and low HDL-c [aOR= 2.30, 95% 315 
CI (1.20-6.83), p =0.03071] were significant independent risk factors associated with 316 
baseline high SHS PWLD-PE (Table 5).  317 
To explore the usefulness of SHS in predicting PE and other APCs, we performed a 318 
multivariate logistic regression model and use the cut-off to generate sensitivity, specificity 319 
and area under the ROC curve. Using high SHS alone as a screening measure yielded 320 
significantly increased odds, a wider area under the ROC curve (AUC), and a high sensitivity 321 
and specificity for identifying PE (aOR= 3.67, AUC= 0.8987, 91.9% and 87.8%), PE 322 
coexisting with IUGR (aOR=2.86, AUC= 0.8378, 91.5% and 75.9%), and stillbirth (aOR= 323 
2.52, AUC= 0.7832, 96.6% and 60.0%) compared to its combination with Mg and Ca (Table 324 
6).  325 
Also using high SHS alone as a screening measure yielded a better predictive and diagnostic 326 
accuracies for identifying PE coexisting with HELLP syndrome (aOR=2.08, AUC= 0.8009, 327 
97.2% and 63.8%), AKI (aOR= 2.2, AUC= 0.8246, 95.3% and 70.0%) and dyslipidaemia 328 
(aOR=2.80, AUC= 0.8205, 95.7% and 68.4%) compared to its combination with Mg and Ca 329 
(Table 7).  330 
Meanwhile, a novel combination of SHS, Mg and Ca levels yielded a fair discriminating power, 331 
sensitivity and specificity for identifying PE coexisting with APCs. Particularly, a combination 332 
of high SHS and low Ca levels yielded a better predictive power and diagnostic performance 333 
compared to the combination of high SHS and low Mg. Overall, SHS is an independent 334 
predictive and screening measure for PE and its associated APCs (Tables 6 and 7).  335 
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 336 
As shown in Fig. 3, high SHS yielded a significantly high discriminating power (area under 337 
the ROC curve) for identifying all PE women (AUC= 0.7832; p <0.0001) (Fig. 3a), PE 338 
coexisting with IUGR (AUC= 0.8378; p <0.0001) (Fig. 3b), stillbirth (AUC=0.8205; p 339 
<0.0001) (Fig. 3c), HELLP syndrome (AUC= 0.8009; p <0.0001) (Fig. 3d), AKI (AUC= 340 
0.8378; p <0.0001) (Fig. 3e), and dyslipidaemia (AUC= 0.8987; p <0.0001) (Fig. 3f)  341 
   342 
 343 
 344 
 345 
 346 
Discussion 347 
For the first time in a Ghanaian Suboptimal Health Cohort Study (GHOACS), the 348 
present study determined the usefulness of SHSQ-25 for prediction and early 349 
identification of normotensive pregnant women (NTN-PW) likely to develop PE and 350 
other adverse pregnancy complicat ions (APCs).  351 
One major finding of the present study indicated that 61.7% of high SHS NTN -352 
PW developed PE compared to 17.6% for optimal health NTN-PW (Tables 2 and 3). At 353 
baseline (10-20 weeks), normotensive pregnant women who had high SHS were at 354 
approximately 4-fold increased odds of developing PE after adjusting for maternal age, 355 
gestational age, parity, gravidity, family history of hypertension, maternal BP, history of 356 
spontaneous abortion, pre-gestational BMI, high TG and low HDL. This signifies that the 357 
association between SHS and PE is independent of these confounders. Moreover, high 358 
SHS at baseline (10-20 weeks gestation) yielded a sensitivity of 91.9%, a specificity of 359 
87.8% and an area under the ROC curve (AUC)/ discriminating power of 89.9% (Fig. 3a),  360 
indicating the power of high SHS for predicting the onset of PE. The ability of high SHS 361 
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at baseline to predict the onset of PE signifies that SHSQ-25 may be an important measure 362 
in predictive, preventive and personalise medicine (PPPM).  363 
In the present study, the link between SHS and PE onset was further supported by 364 
a significant relationship between the individual SHS-specific domains and the incidence 365 
of PE. Particularly, the incidence of PE increased with increasing SHS-specific domains 366 
score for fatigue, cardiovascular complaints, digestive system disorder, immune health 367 
disorder and mental health complaints (Table 4). The probable reason(s) for this 368 
relationship between SHS and the onset of PE are not currently understood. PE which is 369 
a multi-systemic and multi-organ syndrome, however, may share a common biologica l 370 
and/or physiological pathway to SHS. Particularly, SHS is associated with hypertension 371 
and other cardiovascular-related disorders [17, 18, 20] which links to PE. SHSQ-25 372 
evaluates the general health status via five specific domains: fatigue, cardiovascu la r 373 
system, digestive system, immune system and mental health.  Although the exact  374 
aetiology of PE is still unknown, previous studies have linked PE onset to immune [28, 375 
29] and cardiovascular disease [30, 31]. Additionally, the clinical symptoms of PE have 376 
also been associated with digestive disorders such as hyperemesis gravidarum (severe 377 
vomiting), nausea, and constipation [32], fatigue [32] and mental health [33]. All these 378 
symptoms are significant components of SHS and thus uncover the hidden link between 379 
SHS and the onset of PE, although we are the first to study the factors together. The 380 
probable explanation for the association between PE and the five SHS-specify domains 381 
may be due to the common symptoms, biological and/or physiological pathway both share 382 
[32, 33, 30, 29, 28, 31]. Hence, integration of SHSQ-25 as a SHS screening tool in 383 
antenatal care will generate a new approach with potential for early identification of 384 
normotensive pregnant women likely to develop PE, thereby creating a window of 385 
opportunity for PPPM. Here, PPPM intervention will promote adequate patients 386 
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surveillance, risk stratification, optimal diagnosis, prediction of adverse drug to drug 387 
interactions and early disease identification [9, 10, 8]. 388 
Previous case-control studies by Ephraim et al. [34] among a Ghanaian populat ion 389 
and Guo et al. [35] among a Chinese population [34, 35] have observed several serum 390 
biochemical changes including reduced levels of magnesium and calcium in preeclampt ic 391 
pregnancies at the point of diagnosis, although these imbalances are not commonly 392 
reported in early normotensive pregnancies prior to the onset of PE. However, at baseline 393 
(10-20 weeks gestation) in the present longitudinal cohort study, high SHS NTN-PW who 394 
later developed PE at 32-42 weeks gestation had significantly reduced levels of 395 
magnesium and calcium compared to optimal health NTN-PW (Table 2). High SHS NTN-396 
PW had low serum magnesium and calcium levels with 3- and 4-fold increased odds 397 
respectively, compared to those with optimal health status (Table 5). This relationship is 398 
novel.  This novel finding signifies that SHS can represent a tool for PPPM by predict ing 399 
an early risk of low dietary magnesium and calcium intake. A cross-sect ional study in a 400 
Ghanaian population observed significantly low Mg and Ca levels among NTN-PW 401 
compared to non-pregnant women [36]. The low calcium levels at baseline may have led  402 
to hypertension by stimulating an increased release of renin and parathyroid hormone, 403 
which in turn increases intracellular calcium in smooth muscle, culminating in 404 
vasoconstrict ion [34]. The observed low magnesium levels may also be due to increased  405 
clearance by the renal system, reduced dietary intake, haemodilution caused by expansion 406 
of the extracellular space and high consumption of minerals by the growing foetus [35, 407 
34]. From the PPPM perspective, SHS can be used to predict early signs of calcium and 408 
magnesium malnutrition and also inform therapeutic options needed for high SHS NTN-409 
PW likely to develop PE.   410 
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Preeclampsia is a multifactorial syndrome, indicating that it can co-exist with 411 
other adverse pregnancy complications (APCs) such as intrauterine growth restrict ion 412 
(IUGR), stillbirth, haemolysis elevated liver enzymes and low platelet count (HELLP) 413 
syndrome [3, 37], dyslipidaemia [38, 39] and acute kidney injury (AKI) [40]. These 414 
reports agree with the findings of the present study although the identification of these 415 
APCs is mostly delayed and diagnosis occurs late in gestation which highly support s 416 
earlier PPPM approach. For this purpose, we performed a predictive model using baseline 417 
high SHS scores alone as well as an algorithm of high SHS score, low magnesium and/or 418 
calcium and generated an area under ROC curve (AUC)/ discriminating power, sensitivity 419 
and specificity to predict and identify the risk of PE co-existing with other APCs. Our 420 
findings indicated that using high SHS score alone can yield a better predictive odds ratio, 421 
sensitivity and specificity than its combination with low magnesium and calcium levels. 422 
Conversely, a combination of SHS with Mg and Ca levels yielded a signif icantly high 423 
specificity but low sensitivity compared to using SHS alone (Tables 6 and 7). This 424 
confirms our findings that SHS is an independent predictor of PE and other APCs that  425 
supports the paradigm shift of clinical medicine from delayed medical intervention to 426 
PPPM.  427 
Particularly in the present study, high SHS NTN-PW at baseline were at 3-fold  428 
increased odds of developing PE-coexisting with IUGR at 32-42 weeks gestation. This 429 
occurred at 83.8% discriminating power (Fig. 3b), a sensitivity of 91.5% and a specificity 430 
of 75.9% (Table 6). The occurrence of IUGR may be due to endothelial dysfunction [41]. 431 
Our previous cross-sectional study among adult European population found an 432 
association between SHS and endothelial dysfunction, and thus the relationship between 433 
SHS and IUGR, may possibly be due to endothelial dysfunction [20]. Endothelial 434 
dysfunction may be caused by placental hypoxia, oxidative stress and nitric oxide 435 
deficiency originating from poor extravillous trophoblast invasion and incomplete 436 
18 
 
maternal artery remodeling [42]. Another factor that may explain PE coexisting with 437 
IUGR is maternal psychosocial stress [43, 7, 44], previously shown by a cross-sect iona l 438 
study among a Chinese population that found an association between SHS and 439 
psychosocial stress [22] potentially associated with fatigue which is one of the SHS-440 
specific domains.  441 
Another novel finding of the present study was a significant association between 442 
SHS and PE coexisting with stillbirth. Normotensive pregnant women who had high SHS 443 
at baseline (10-20 weeks gestation) were 2.5 times more likely to develop PE-coexist ing 444 
with stillbirth during birth (32-42 weeks gestation). At 2.5-fold predictive odds ratio for 445 
high SHS, a  sensitivity of 96.6%, specificity of 60.0% (Table 6) and a discriminating 446 
power of 78.3% (Fig. 3c) was observed. Preeclampsia is known to complicate the 447 
development of stillbirth and the underlying cause has been linked to placental 448 
insufficiency and incomplete maternal arteries remodeling [3, 42, 45]. Thus, SHSQ-25 449 
suggests a non-invasive subjective measure for the identification of stillbirth strongly 450 
emphasizes the advantage of PPPM to prevent this fatal outcome.  451 
SHS and PE-coexisting HELLP syndrome in this study is another novel find ing. In the 452 
present study, HELLP syndrome identified by haemolysis (high levels of LDH), elevated  453 
liver enzymes (ALP, AST, ALT, and GGT) and low platelet count was observed at a 454 
higher rate in PE women compared to NTN-PW. Pregnant women who had high SHS at 455 
baseline (10-20 weeks) were 2.08 times more likely to develop PE-coexisting HELLP 456 
syndrome at 32-42 weeks (Table 7). This syndrome, which is characterised by 457 
microangiopathic anaemia, thrombocytopaenia and periportal hepatic necrosis [25] is a 458 
known cause of eclampsia-associated mental health problems in pregnancy [33]. Our 459 
findings indicated that high SHS can identify PE-coexisting HELLP syndrome at 97.2% 460 
sensitivity, 63.8% specificity and a discriminating power (AUC) (Fig. 3d) of 80.1%. 461 
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Hepatic involvement in PE may be explained by precipitation of fibrin within the portal 462 
and periportal areas of the liver lobule and hepatic arterial vasospasm resulting in hepatic 463 
cell necrosis and lobular ischaemia [25]. The link between SHS and PE-coexisting with 464 
HELLP syndrome could be also related to the mental health phenomenon both share, 465 
though this mechanism is speculative. Early detection of mental health complaints using 466 
SHSQ-25 in pregnancy will inform clinicians of the likelihood of HELLP syndrome 467 
developments.  468 
Acute kidney injury (AKI) is not commonly associated with normotensive 469 
pregnancy, but can occur in pregnancies potentially associated with severe PE, HELLP 470 
syndrome [26, 40], intrauterine fetal death, and stillbirth [46]. In the present study, AKI 471 
was diagnosed based on either a sudden increase in serum creatinine ≥88.4µmol/ lo r 472 
oligoanuria or the need for dialysis [46]. Our present study found that increased creatinine 473 
levels were associated with high SHS women who developed PE compared to 474 
normotensive pregnant women. Using high SHS score at baseline as a predictive measure, 475 
a discriminating power of 82.5% (Fig. 3e), a sensitivity of 95.3%, aspecificity of 70.0% 476 
and a predictive odds ratio of 2.2 were generated to identify the risk of PE co-exist ing 477 
with AKI.  Since high SHS score was associated with high creatinine levels, which is the 478 
hallmark of AKI, early detection of abnormal creatinine will inform clinicians the 479 
likelihood of AKI in pregnancy and thus supporting the integration and use of SHSQ-25 480 
as a potential SHS measure in antenatal care.  481 
In a previous prospective cohort study among NTN-PW in a Turkish populat ion, 482 
early dyslipidaemia (10-20 weeks) was found to be a significant risk factor for PE [39]. 483 
This agrees with the present study findings, as a low HDL-c and high TG at baseline (10-484 
20 weeks gestation) were associated with high SHS NTN-PW who later developed PE. 485 
Thus hypertriglyceridaemia [47] is ideal for early PE detection and management. Using 486 
high SHS score as an independent measure a high predictive odds ratio (2.8), 487 
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discriminating power of 82.1% (Fig. 3f) and diagnostic performance (sensitivity of 95.7% 488 
and specificity of 68.4%) was observed for the prediction of PE-coexisting with 489 
dyslipidaemia (Table 7). An association between SHS and cardiovascular and/or 490 
cardiometabolic risk has been established in our previous studies [18, 20]. Although 491 
pregnancy-induced hyperlipidaemia may be physiologic, dyslipidaemia may predispose 492 
the mother to atherosclerosis and directly contributes to cardiovascular disease (CVD) 493 
[27, 47].  The development of dyslipidaemia may be associated with systemic 494 
inflammation originating from N-glycosylation-induced changes in immunoglobulin G (IgG) 495 
structure and function [48]. Since, dyslipidaemia remains one of the predisposing factors 496 
PE [30],  early identification of women at risk of dyslipidaemia would be an opportunity 497 
for selective monitoring and management. This supports the need to integrate SHSQ-25 498 
in antenatal care as a dynamic screening tool for PE complicated by dyslipidaemia. Since 499 
SHS correlates with cardiovascular index like dyslipidaemia it will generate an early risk 500 
stratification for PE participants at risk of cardiovascular disease as well as promote an 501 
opportunity personalised medicine. 502 
To our knowledge, this is the first study integrating SHS as a screening tool in 503 
pregnancy and childbirth, and the largest prospective cohort study in a Ghanaian 504 
population. Nevertheless, there were some limitations. First, the recruitment of 505 
participants in this present study was single-hospital centred, in the sense that only one 506 
teaching hospital was involved, thus, there was a possibility of ethnic bias as most of the 507 
participants were Akan’s and few were distributed across other ethnic groups.  Second , 508 
this study could not recruit baseline participants at early but rather late first trimester of 509 
pregnancy, hence we could not perform SHS evaluation at 21-31 weeks gestation to see 510 
the changes in health status over time in relation to the risk of PE. The findings of this  511 
study, however, is novel and, thus, further studies are needed in another population to 512 
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establish the observed association. The relationship between SHS and PE as well as PE 513 
coexisting with APCs, although not well-understood, may have an interconnection with 514 
placenta-derived factors (angiogenic growth mediators) and oxidative stress, which are 515 
key factors contributing to the pathogenesis of PE. Our next study will address this by 516 
evaluating an association between SHS, angiogenic growth mediators and oxidative stress 517 
among NTN-PW in this on-going Ghanaian Suboptimal Health Cohort Study (GHOACS). 518 
Conclusion  519 
In summary, a higher percentage of high SHS NTN-PW at baseline are more likely 520 
to developed PE. The incidence of PE increased with increasing SHS-specific domain 521 
scores. This association was supported by a significantly deranged haematobiochemica l 522 
profile, an increased adjusted odds ratio, a wider area under the ROC curve, and a better 523 
sensitivity and specificity in favour of high SHS NTN-PW compared to optimal health 524 
participants. Overall, high SHS in early pregnancy is an independent risk factor of PE as 525 
well as PE coexisting with IUGR, stillbirth, HELLP syndrome, AKI and dyslipidaemia . 526 
Integration of SHSQ-25 as a screening tool in both early antenatal care and follow-527 
up of pregnant women will allow early detection of adverse pregnancy complicat ions 528 
whilst creating an opportunity for PPPM policies such as screening programmes, 529 
education, risk assessment and targeted prevention. The idea of SHS (Sub optimal Health 530 
Status) profile – highly correlated with biochemical/ physiological risk factors – implies 531 
that we can “feel” the inside pathologies – though usually perceived as “subjective”, is 532 
very important for self-education/responsibility, suggesting a potential for “subject ive” 533 
PPPM approach. Hence, SHSQ-25 can be used as an alternative health pre-screen ing 534 
measure in clinical laboratory-limited communities, fields and community health centres 535 
in sub-Saharan African countries on emergency situations.                                                                                                   536 
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Table 1. Baseline (10-20 weeks gestation) sociodemographic characteristics of normotensive 741 
pregnant women stratified by high SHS and optimal health status (OHS) 742 
Characteristics 
Total  
(N=498) 
High SHS  
(N=248) 
OHS          
(N=250)   Statistics p-value 
Highest Level of Education    1.794, 3 0.6163 
Unschooled 3(0.4) 1(0.4) 2(0.8)   
Primary 168(33.7) 82(33.1) 86(34.4)   
Secondary 208(41.8) 110(44.4) 98(39.2)   
Tertiary 119(23.9) 55(22.2) 64(25.6)   
Marital Status    0.207, 2 0.9018 
Never married 78(15.7) 37(14.9) 41(16.4)   
Married 416(83.5) 209(84.3) 207(82.8)   
De-facto 4(0.8) 2(0.8) 2(0.8)   
Ethnicity    2.768, 3 0.4288 
Akan 407(81.7) 196(79.0) 211(84.4)   
Ga-Adangbe 9(1.8) 6(2.4) 3(1.2)   
Mole Dagbani 75(15.1) 42(16.9) 33(13.2)   
Ewe 7(1.4) 4(1.6) 3(1.2)   
Occupation    0.199, 2 0.3687 
Unemployed 47(9.4) 28(11.3) 19(7.6)   
Formal 122(24.5) 59(23.8) 63(25.2)   
Informal 329(66.1) 161(64.9) 168(67.2)   
Basic income (GH₡)    2.777, 3 0.4273 
None 47(9.4) 28(11.3) 19(7.6)   
Low (<500.0) 191(38.4) 92(37.1) 99(39.6)   
Middle (500.0-1000.0) 170(34.1) 87(35.1) 83(33.2)   
High (>1000.0) 90(18.1) 41(16.5) 49(19.6)   
Parity     7.706, 2 0.0212 
Nulliparous 184(36.9) 102(41.1) 82(32.8)   
Primiparous 135(27.1) 54(21.7) 81(32.4)   
multiparous 179(36.0) 92(37.1) 87(34.8)   
Gravidity    51.54, 1 <0.0001 
Primigravida 233(46.8) 156(62.9) 77(30.8)   
Multigravida 265(53.2) 92(37.1) 173(69.2)   
FH of Hypertension    0.230,1 0.6314 
Yes 110(22.1) 57(23.0) 53(21.2)   
No 388(77.9) 191(77.0) 197(78.8)   
History of spontaneous Abortion    5.083, 1 0.0001 
Yes 139(27.9) 91(36.7) 48(19.2)   
No 359(72.1) 157(63.3) 202(80.8)   
Previous CS    0.085, 1 0.7701 
Yes 99(19.9) 48(19.4) 51(20.4)   
No  399(80.1) 200(80.6) 199(79.6)   
Dipstick proteinuria (<0.3g/g/24hr) 498(100.0) 248(100.0) 250(100.0)  1.0000 
Age (years) 29.64 ± 5.98  29.42 ± 5.92  29.60 ± 6.08 0.667 0.5049 
Gestational age (weeks) 16.98 ± 2.01  16.97 ± 2.08  17.04 ± 1.98 0.060 0.9586 
SBP (mmHg) 114.7 ± 10.57  116.0 ± 11.00  113 .2 ± 10.01 2.703 0.0036 
DBP (mmHg) 72.58 ± 9.26 73.0 ± 8.78 71.8 ± 8.42 1.618 0.1341 
Pre-gestational BMI (Kg/m2) 27.04 ± 4.83 26.86 ± 4.74 27.07 ± 4.92 0.405 0.6887 
Gestational BMI (Kg/m2) 27.33 ± 4.81 27.32 ± 4.74 27.2 ± 4.92 0.298 0.7658 
Values are presented as mean ± SD, frequency (percentage), CS: caesarean section; GH₡: Ghana cedi; SBP: systolic blood 743 
pressure; DBP: diastolic blood pressure. OHS: optimal health status744 
28 
 
Table 2. Baseline (10-20 weeks gestation) clinical and haematobiochemical profile among high SHS and OHS normotensive pregnant women who 745 
later developed preeclampsia (PWLD-PE) compared to NTN-PW who did not develop PE 746 
 High SHS at 10-20 weeks (Baseline)  OHS at 10-20 weeks (Baseline)  
Parameter PWLD-PE (N=153) NTN-PW(N=95) p-value PWLD-PE (N=44) NTN-PW (N=206) p-value 
Age (years) 28.86 ± 6.08  30.24 ± 5.11 0.0664 28.07 ± 7.21  30.03 ± 5.76 0.0531 
Gestational age (weeks) 16.93 ± 1.95  17.04 ± 2.26 0.9768 17.11 ± 1.76 17.02 ± 1.98 0.9933 
SBP (mmHg) 118.3 ± 10.84  112.4 ± 10.52 <0.0001 114.0 ± 10.95 115.1 ± 9.54 0.9641 
DBP (mmHg) 75.05 ± 9.49 69.91 ± 8.93 0.0002 72.70 ± 9.45 71.61 ± 9.29 0.8932 
Pre-gestational BMI (Kg/m2) 26.95 ± 4.68 27.12 ± 4.44 0.7712 26.64 ± 5.04 27.15 ± 5.01 0.9186 
Gestational BMI (Kg/m2) 27.45 ± 4.64 27.11 ± 4.39 0.9475 27.01 ± 5.10 27.25 ± 5.00 0.9910 
Mg (mmol/l) 0.88 ± 0.24 0.96 ± 0.22 0.0082 0.94 ± 0.12 0.99 ± 0.13 0.2867 
Adjusted Ca (mmol/l)  2.03 ± 0.37 2.20 ± 0.31 0.0004 2.13 ± 0.44 2.26 ± 0.31 0.0573 
Na (mmol/l)  136.4 ± 2.0 136.2 ± 1.96 0.9652 136.5 ± 2.17 136.2 ± 2.01 0.9441 
K (mmol/l) 4.18 ± 0.41 4.20 ± 0.48 0.9605 4.12 ± 0.35 4.17 ± 0.31 0.8641 
Cl-(mmol/l) 105.6 ± 2.19 105.5 ± 2.42 0.9987 105.8 ± 2.40 105.6 ± 2.33 0.9394 
LDH (IU/L)  187(138.5-198.0) 168(139-196) 0.6822 192(147.5-198) 187(139-196) 0.3045 
AST (IU/L) 17.2(14.30-27.1) 16.1(13.8-29.4) 0.9324 15.7(13.7-19.3) 15.2(13.6-19.30) 0.9918 
ALT (IU/L) 14.3(10.7-28.4) 10.7(10.2-15.3) <0.0001 12.6(10.2-17.3) 11.3(10.3-14.6) 0.9997 
ALP (IU/L) 97(77.3-105) 70(56.3-100) 0.0002 95(90.8-111.8) 91.5(65-105) 0.0006 
GGT (IU/L) 10.9(10.1-15.1) 11.3(10.1-15.4) 0.9991 10.3(9.51-12.2) 10.3(9.8-12.2) 0.9999 
Total Protein (g/L) 68.08 ± 2.21 67.76 ± 2.20 0.6943 67.74 ± 2.46 67.97 ± 2.23 0.9283 
Albumin (g/L) 37.0 ± 1.26 36.81 ± 1.26 0.6741 36.84 ± 1.38 36.91 ± 1.29 0.9870 
Urea (mmol/l) 4.34 ± 2.08 3.55 ± 1.36 0.0011 3.58 ± 1.55 3.61 ± 1.33 0.9996 
Creatinine (µmol/l) 65.61 ± 16.49 56.92 ± 10.75 <0.0001 63.84 ± 11.22 59.47 ± 11.0 0.1753 
UA (µmol/l) 326.0 ± 39.77 286.0 ± 44.8 0.0034 304.9 ± 38.21 275.3 ± 48.98 0.0039 
Hb (g/dL) 10.92 ± 0.62 11.57 ± 0.63 0.0573 11.74 ± 0.56 11.70 ± 0.57 0.9705 
RDW-CV (%) 13.70 ± 1.34 13.67 ± 1.31 0.9989 13.56 ± 1.34 13.64 ± 1.24 0.9802 
PLT (X109 / L) 284.5 ± 85.3 300.4 ± 85.56 0.5006 292.3 ± 88.78 301.7 ± 89.18 0.9154 
FBG (mmol/L) 4.85 ± 0.76 4.930 ± 0.79 0.0854 5.21 ± 0.76 5.08 ± 0.71 0.6785 
TC (mmol/L) 4.76 ± 1.30 4.70 ± 1.15 0.9801 4.63 ± 1.18 4.65 ± 1.11 0.9997 
TG (mmol/L) 1.56 ± 0.91 1.21 ± 0.48 0.0003 1.44 ± 0.94 1.16 ± 0.41 0.0031 
HDL-c (mmol/L) 1.38 ± 0.31 1.46 ± 0.31 0.1062 1.50 ± 0.27 1.48 ± 0.35 0.9753 
LDL-c (mmol/L) 2.86 ± 1.19 2.93 ± 1.00 0.9709 2.73 ± 1.02 2.79 ± 0.98 0.9801 
Values are presented as mean ± SD; median (IQR); PWLD-PE: Pregnant women who later developed PE. 747 
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Table 3. Clinical and haematobiochemical profile at 32-42 weeks gestation (Birth) among high SHS and OHS participants who developed PE 748 
compared to NTN-PW  749 
 High SHS   OHS  
Parameter PE (N=153) NTN-PW (N=95) p-value PE (N=44) NTN-PW (N=206) p-value 
Age (years) 28.94 ± 6.10  30.28 ± 5.09 0.1718 28.37 ± 7.33  30.46 ± 5.82 0.1480 
Gestational age (weeks) 33.99 ± 2.43  38.12 ± 1.52 <0.0001 35.0 ± 2.25 ‡ 37.98 ± 1.52 <0.0001 
SBP (mmHg) 172.7 ± 16.76  119.8 ± 8.74 <0.0001 160.2 ± 12.29 ‡ 115.1 ± 9.54† <0.0001 
DBP (mmHg) 109.9 ± 10.05 76.34 ± 9.29 <0.0001 109.2 ± 7.89  74.78 ± 8.69 <0.0001 
Pre-gestational BMI (Kg/m2) 26.95 ± 4.68 27.12 ± 4.44 0.7712 26.64 ± 5.04 27.15 ± 5.01 0.9186 
Gestational BMI (Kg/m2) 28.37 ± 4.58 27.99 ± 4.35 0.5230 28.17 ± 4.85 27.98 ± 4.92 0.9948 
Mg (mmol/l) 0.57 ± 0.21 0.99 ± 0.24 <0.0001 0.69 ± 0.19 ‡ 1.11 ± 0.16† <0.0001 
Adjusted Ca (mmol/l)  1.74 ± 0.37 2.25 ± 0.41 <0.0001 1.97 ± 0.23 ‡ 2.49 ± 0.31† <0.0001 
Na (mmol/l)  145.7 ± 3.18 141.2 ± 1.96 <0.0001 143.0 ± 3.66  143.2 ± 2.01 0.0682 
K (mmol/l) 3.56 ± 0.32 3.58 ± 0.35 0.8041 3.60 ± 0.44  3.66 ± 0.38 0.8787 
Cl-(mmol/l) 110.6 ± 2.19 110.5 ± 2.42 0.8767 110.9 ± 2.29 110.6 ± 2.33 0.8471 
LDH (IU/L)  264(227-330.0) 175(146.0-203.0) <0.0001 238(223.5-301.8) ‡ 174.4(146.0-203.0)  <0.0001 
AST (IU/L) 31.9(25.6-47.4) 23.5(19.9-25.7) <0.0001 29.1(24.9-38.58) ‡ 22.5(20.35-25.70)  <0.0001 
ALT (IU/L) 52.0(39.8-72.4) 31.1(24.0-39.2) <0.0001 40.3(37.8-70.0) ‡  30.5(23.8-39.2)  <0.0001 
ALP (IU/L) 383(335-423) 238(195-275) <0.0001 344(263.8-382)  235(203-253)  <0.0001 
GGT (IU/L) 20.4(17.9-47.3) 18.8(17.6-22.9) <0.0001 19.3(17.2-35.6)  17.8(17.3-19.7)  <0.0001 
Total Protein (g/L) 57.90 ± 3.07 62.71 ± 2.20 <0.0001 60.51 ± 2.98 ‡ 62.97 ± 2.23  <0.0001 
Albumin (g/L) 30.93 ± 1.73 33.91 ± 1.26 <0.0001 32.73 ± 1.69 ‡ 34.01 ± 1.25  <0.0001 
Urea (mmol/l) 9.17 ± 2.46 5.67 ± 1.27 <0.0001 8.94 ± 2.10  5.42 ± 1.33  <0.0001 
Creatinine (µmol/l) 107.8 ± 43.43 68.45 ± 11.21 <0.0001 102.0 ± 15.17 66.6 ± 11.0  <0.0001 
UA (µmol/l) 413.5 ± 73.9 314.0 ± 37.3 <0.0001 398.8 ± 72.66 301.6 ± 43.91 <0.0001 
Hb (g/dL) 11.02 ± 0.63 10.97 ± 0.62 0.5212 11.14 ± 0.56 11.10 ± 0.57 0.9705 
RDW-CV (%) 16.40 ± 1.34 16.37 ± 1.31 0.8868 16.26 ± 1.34 16.34 ± 1.24 0.9802 
PLT (X109 / L) 247.7 ± 90.6 292.4 ± 85.56 0.0007 268.5 ± 86.01 293.2 ± 88.76  0.3354 
FBG (mmol/L) 5.58 ± 0.68 5.50 ± 0.70 0.6198 5.67 ± 0.59 5.65 ± 0.71 0.9981 
TC (mmol/L) 5.64 ± 1.29 5.33 ± 0.97 0.1330 5.63 ± 1.16 5.23 ± 0.94  0.1236 
TG (mmol/L) 1.84 ± 0.96 1.42 ± 0.52 <0.0001 1.78 ± 0.79 1.35 ± 0.41 0.0010 
HDL-C (mmol/L) 1.11 ± 0.29 1.18 ± 0.35 0.3284 1.14 ± 0.27 1.19 ± 0.35 0.7798 
LDL-C (mmol/L) 3.59 ± 1.12 3.57 ± 0.98 0.9984 3.49 ± 1.16 3.39 ± 0.87 0.9218 
Birthweight (kg) 1.97 ± 0.01 2.83 ± 0.01 <0.0001 2.69 ± 0.01 2.87 ± 0.01 0.0812 
Values are presented as mean ± SD; median (IQR); † Significant difference compared to high SHS NTN-PW; ‡ Significant difference compared to high SHS PE. Mg: magnesium; Ca: calcium; 750 
Na: sodium; K: potassium; Cl-: chloride; LDH: lactate dehydrogenase; UA: uric acid; RDW: red blood cell distribution width751 
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Table 4. Association between the individual and overall SHS domain scores among 752 
participants at baseline (10-20 weeks gestation) and PE incidence at 32-42 weeks gestation 753 
(n=498) 754 
 PE incidence 
SHS domains r p-value 
Fatigue 0.300 0.0038 
Cardiovascular system 0.291 0.0174 
Digestive system 0.287 0.0291 
Immune system 0.342 0.0010 
Mental health status 0.442 <0.0001 
Overall SHS 0.509 <0.0001 
r: Spearman Rho correlation coefficient. P-values are adjusted for the false discovery rate using Benjamini Hochberg 755 
correction 756 
 757 
 758 
 759 
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Table 5. Univariate and multivariate logistic regression model of baseline clinical and 786 
haematobiochemical profile for risk stratification of high SHS among pregnant women 787 
who later developed-PE (PWLD-PE) 788 
Characteristics Model 1  Model 2  
 cOR (95% CI) p-value aOR (95% CI) p-value 
BP (mmHg)     
Optimal  1.00  1.00  
High-normal 2.96(2.39-4.85) < 0.0001 2.84(1.94-5.40) 0.0314 
Mg (mmol/l)     
Low 3.47(3.16-7.15) <0.0001 2.99(1.29-6.20) 0.0038 
Normal 1.00  1.00  
Adj. Ca (mmol/l)     
Low 4.19(1.19-5.03) <0.0001 4.20(1.57-5.63) <0.0001 
Normal 1.00  1.00  
LDH (IU/L)     
High 2.75(0.60-5.07) 0.0818 1.94(0.76-4.98) 0.2104 
Normal 1.00  1.00  
AST (IU/L)     
High 1.82(0.68-8.14) 0.0518 1.10(0.37-24.2) 0.4613 
Normal 1.00  1.00  
ALP (IU/L)     
High 1.08(0.78-1.93) 0.8054 0.78(0.39-1.57) 0.5944 
Normal 1.00  1.00  
Urea (IU/L)     
High 1.03(0.73-10.51) 0.0910 1.22(0.41-16.55) 0.4729 
Normal 1.00  1.00  
Creatinine (IU/L)     
High 1.15(0.55-7.04) 0.258 1.39(1.04-6.33) 0.1449 
Normal 1.00  1.00  
Uric Acid (µmol/l)     
High 1.18(0.41-3.88) 0.8531 0.48(0.15-1.53) 0.3138 
Normal 1.00  1.00  
Hb (g/dl)     
Anaemia 1.58(1.01-2.62) 0.0597 1.81(0.74-4.38) 0.2276 
Non-anaemia 1.00  1.00  
FBG (mmol/L)     
High Normal 1.85(0.81-3.85) 0.1068 0.84(0.31-2.28) 0.7942 
Normal 1.00  1.00  
TC (mmol/L)     
High 1.30(0.94-2.03) 0.2750 1.82(0.81-4.10) 0.1884 
Normal 1.00  1.00  
TG (mmol/L)     
High 2.14(1.08-4.79) 0.0206 2.08(1.12-4.27) 0.0151 
Normal 1.00  1.00  
HDL (mmol/L)     
Low 2.44(1.15-7.05) 0.0418 2.30(1.20-6.83) 0.0307 
Normal 1.00  1.00  
LDL (mmol/L)     
High 1.38(0.689-2.67) 0.0890 1.23(0.50-3.05) 0.8252 
Normal 1.00  1.00  
cOR: crude odds ratio; aOR: adjusted odds ratio; CI: confidence interval; 1.00: reference category; Model 2 adjusted for maternal 789 
age, parity, gravidity, family history of hypertension, maternal blood pressure, history of spontaneous abortion, pre-gestational 790 
BMI 791 
 792 
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Table 6. Predictive performance of baseline high SHS score with serum Mg and Ca levels for prediction and diagnosis of PWLD-PE and 793 
PE-coexisting IUGR and stillbirth at 32-42 weeks gestation 794 
 Model 1 Model 2        
Baseline SHS cOR (95% CI) aOR (95% CI) p-value Sensitivity (95% CI) Specificity (95% CI) PPV NPV LR+ AUC 
 Overall PE          
High SHS  3.51 (2.18-9.41)* 3.67 (2.73- 8.32) <0.0001 91.9 (87.6-94.8) 87.8 (83.2-91.3) 87.1 92.4 7.55 0.8987 
OHS  1.00  1.00        
High SHS + Low Mg 3.00 (2.51-7.33)* 2.58 (1.15- 5.95) 0.0381 66.5 (59.6-72.7) 90.9 (86.3-94.4) 52.4 81.9 2.67 0.6212 
OHS + Normal Mg 1.00 1.00        
High SHS + Low Ca 2.82 (2.06- 8.41)* 2.22 (1.51- 6.72) 0.0461 70.6 (61.1-78.9) 93.9 (90.4-99.7) 58.3 82.9 2.71 0.7559 
OHS + Normal Ca 1.00 1.00        
PE+ IUGR           
High SHS  3.19 (2.01-8.87)* 2.86 (1.62- 8.87) <0.0001 91.5 (86.6-94.8) 75.9 (70.8-80.4) 70.1 93.6 3.81 0.8378 
OHS  1.00 1.00        
High SHS + Low Mg 1.04 (0.57-7.35) 1.37 (0.92- 6.09) 0.0934 22.2 (10.1-39.2) 80.3 (79.2-93.7) 33.3 82.6 2.06   0.5211  
OHS + Normal Mg              1.00              1.00        
High SHS + Low Ca 2.33 (2.26-8.07)* 2.08 (1.68- 8.32) 0.0328 62.5 (48.6-75.1)      89.2 (83.2-89.5)  46.7 83.2 2.25 0.6462 
OHS + Normal Ca 1.00 1.00        
PE + Stillbirth          
High SHS  2.61 (2.60-9.00)* 2.52 (2.34-10.12) <0.0001 96.6(89.8-99.1) 60.0(55.3-64.7) 33.9 99.8 2.41 0.7832 
OHS  1.00 1.00        
High SHS + Low Mg 1.87 (1.61- 9.38)* 1.91 (1.53- 11.92) 0.0430 37.5 (15.2-64.6) 90.8 (86.1-94.3) 23.1 95.2 4.06 0.5805 
OHS + Normal Mg 1.00 1.00        
High SHS + Low Ca 2.35 (1.85-10.56)* 2.67 (2.40- 9.74) <0.0001 72.7 (49.8-89.3) 86.2 (84.6-89.9) 62.8 96.3 2.82 0.7203 
OHS + Normal Ca 1.00 1.00        
cOR: crude odds ratio; aOR: adjusted odds ratio; CI: confidence interval; 1.00: reference category; Model 1: unadjusted odds ratio. Model 2: Model adjusted for adjusted for maternal age, parity, 795 
gravidity, family history of hypertension, maternal blood pressure, history of spontaneous abortion, pre-gestational BMI, low HDL, and high TG. HSHS: high SHS; OHS: optimal health status; 796 
Mg: magnesium; Ca: albumin-adjusted calcium; IUGR: intrauterine growth restriction. * indicates significant crude odds ratio (p <0.05).  797 
 798 
 799 
 800 
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Table 7. Predictive performance of baseline high SHS score with serum Mg and Ca levels for prediction and diagnosis of PE-coexisting 801 
with HELLP syndrome, acute kidney injury (AKI) and dyslipidaemia at 32-42 weeks gestation 802 
Baseline SHS Model 1 Model 2        
 cOR (95% CI) aOR (95% CI) p-value Sensitivity (95% CI) Specificity (95% CI) PPV NPV LR+ AUC 
PE+ HELLP syndrome          
High SHS  2.47 (1.88- 9.25)* 2.08 (1.95- 6.83) 0.0001 97.2 (91.5-99.4) 63.8 (58.1-67.6) 41.5 98.8 2.62 0.8009 
OHS  1.00 1.00        
High SHS + Low Mg 1.59 (1.09- 6.32)* 1.97 (1.30- 8.14) 0.0225 66.5 (59.6-72.7) 90.9 (86.3-94.3)  13.1   97.6 4.11 0.6437 
OHS + Normal Mg 1.00 1.00        
High SHS + Low Ca 1.75 (1.31- 7.04)* 2.05 (1.39- 5.36) 0.0013 74.3 (44.9-92.2) 78.3 (62.7-73.5)  16.7   97.5 2.80 0.7310 
OHS + Normal Ca 1.00 1.00        
PE + AKI          
High SHS  2.15 (1.33- 5.31)* 2.20 (1.58- 6.03) 0.0051 95.3(90.4-97.8) 70.0(64.6-74.2)  57.3  97.1 3.14 0.8246 
OHS  1.00 1.00        
High SHS + Low Mg 1.61 (1.53- 8.47)* 1.84 (1.36- 7.58) 0.0330 31.0(15.3-50.8) 91.1(86.6-94.5)  31.0   91.1 3.49 0.5023 
OHS + Normal Mg 1.00 1.00        
High SHS + Low Ca 2.08 (1.74- 4.82)* 2.13 (1.50- 5.10) 0.0018 72.6(58.3-84.1) 73.8(67.3-79.6)  40.2   91.7 2.77 0.7630 
OHS + Normal Ca 1.00 1.00        
PE + dyslipidaemia          
High SHS  2.77(1.80- 9.07)* 2.80 (2.30- 10.35) 0.0004 95.7 (90.7-98.2) 68.4 (63.3-72.9) 54.5 97.6 3.02 0.8205 
OHS  1.00 1.00        
High SHS + Low Mg 1.29 (1.02- 4.16) 1.18 (0.80- 7.20) 0.0599 50.0(6.7-93.2) 90.8(86.2-94.3) 9.1   99.0 5.45 0.6321 
OHS + Normal Mg 1.00 1.00        
High SHS + Low Ca 1.64 (1.00- 7.13) 1.52 (0.79- 9.06) 0.1244 60.0(14.7-94.7) 73.7(67.2-79.5) 5.1   98.7 2.28 0.6594 
OHS + Normal Ca 1.00 1.00        
cOR: crude odds ratio; aOR: adjusted odds ratio; CI: confidence interval; 1.00: reference category; Model 1: unadjusted odds ratio. Model 2: Model adjusted for maternal age, gestational age, 803 
parity, gravidity, family history of hypertension, maternal blood pressure, history of spontaneous abortion, pre-gestational BMI, low HDL and high TG. HSHS: high SHS; OHS: optimal health 804 
status; Mg: magnesium; Ca: albumin-adjusted calcium; HELLP: haemolysis elevated liver enzymes and low platelet count.  * indicates significant crude odds ratio (p <0.05). 805 
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